These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11516778)

  • 21. Modulation of immune responses with transcutaneously deliverable adjuvants.
    Partidos CD; Beignon AS; Briand JP; Muller S
    Vaccine; 2004 Jun; 22(19):2385-90. PubMed ID: 15193399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines--challenges in delivery.
    Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
    Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.
    Bielinska AU; O'Konek JJ; Janczak KW; Baker JR
    Vaccine; 2016 Jul; 34(34):4017-24. PubMed ID: 27317451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems.
    Foged C
    Ther Deliv; 2011 Aug; 2(8):1057-77. PubMed ID: 22826868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin 12 and innate molecules for enhanced mucosal immunity.
    Boyaka PN; Lillard JW; McGhee J
    Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of specific cytotoxic activity for bovine herpesvirus-1 by DNA immunization with different adjuvants.
    Langellotti CA; Pappalardo JS; Quattrocchi V; Mongini C; Zamorano P
    Antiviral Res; 2011 Jun; 90(3):134-42. PubMed ID: 21443903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR; Kiyono H
    Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.
    Bagley K; Xu R; Ota-Setlik A; Egan M; Schwartz J; Fouts T
    Hum Vaccin Immunother; 2015; 11(9):2228-40. PubMed ID: 26042527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic biomimetic supra molecular Biovector (SMBV) particles for nasal vaccine delivery.
    von Hoegen P
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):113-25. PubMed ID: 11516783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fully mobilizing host defense: building better vaccines.
    Raychaudhuri S; Rock KL
    Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterial toxins as mucosal adjuvants.
    Freytag LC; Clements JD
    Curr Top Microbiol Immunol; 1999; 236():215-36. PubMed ID: 9893362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination.
    Wang T; Wang N
    Curr Pharm Des; 2015; 21(36):5245-55. PubMed ID: 26412356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant effects of interleukin-2 co-expression with VP60 in an oral vaccine delivered by attenuated Salmonella typhimurium against rabbit hemorrhagic disease.
    Deng Z; Geng Y; Wang K; Yu Z; Yang PO; Yang Z; He C; Huang C; Yin L; He M; Tang L; Lai W
    Vet Microbiol; 2019 Mar; 230():49-55. PubMed ID: 30827404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.
    Zuckermann FA; Martin S; Husmann RJ; Brandt J
    Adv Vet Med; 1999; 41():447-61. PubMed ID: 9890035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simple nanoliposomes encapsulating
    Bo R; Sun Y; Zhou S; Ou N; Gu P; Liu Z; Hu Y; Liu J; Wang D
    Int J Nanomedicine; 2017; 12():6289-6301. PubMed ID: 28894367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in veterinary vaccine adjuvants.
    Singh M; O'Hagan DT
    Int J Parasitol; 2003 May; 33(5-6):469-78. PubMed ID: 12782048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.